METASTATIC BREAST CARCINOMA

This study tested whether adding an immunotherapy drug (pembrolizumab) to standard hormone therapy (letrozole or fulvestrant) and a targeted drug (palbociclib) could shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor positive (ER+) breast cancer…

This early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…

This study tests whether adding a drug called copanlisib to the usual two-drug therapy (fulvestrant and abemaciclib) works better for people with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) that has spread. The trial involves 24 participant…

This study tests whether a drug called olaparib (a PARP inhibitor) works better alone or combined with atezolizumab (an immunotherapy) for people with advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 participants with locally advanced or metastatic dise…

This early-phase trial tested a combination of two drugs—low-dose cyclophosphamide and veliparib—in 35 people with HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combo could shrink tumors. While n…

This study tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. About 600 adults with breast cancer that had spread or come back took part. T…

This early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This study tests whether a natural substance called GM1 can prevent or reduce nerve damage (pain, numbness, tingling in hands and feet) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo a…

This study tests whether a special type of PET/CT scan (FDG-PET/CT) can better measure how well treatment is working in breast cancer that has spread to the bones. About 138 people with this type of cancer will get the scan before and after starting treatment. The goal is to see …

This study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …

This study looks at whether watching a short video can help people with metastatic cancer better understand tumor genomic testing. About 243 adults with advanced breast, lung, or other solid tumors will watch the video and answer questions before and after. The goal is to see if …

This study aims to create a large collection of blood and tumor samples from 300 people whose breast cancer has spread or returned. By linking these samples with medical information, researchers hope to learn why the cancer spreads and why people respond differently to treatments…